U.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photoand its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored COVID-19 booster shot. The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot's safety, tolerability and immunogenicity, or the ability to generate immune response.
The trial is being conducted in the United States and the companies aim to enroll 180 volunteers between the ages of 18 and 64. The first participant in the study was dosed earlier this week.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer and BioNTech creating combined flu, COVID vaccineThe companies said that 180 U.S. adults ages 18-64 are part of the Phase 1 study. It administered the first dose of the combined vaccine this week.
Read more »
Pfizer-BioNTech testing combination flu-COVID-19 vaccineThe WHO estimates 290,000 to 650,000 people worldwide die of flu-related causes every year. About 1.1 million people in the U.S. have died from COVID-19.
Read more »
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Read more »
Pfizer says study shows vaccinating pregnant women protects newborns from RSVThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
Read more »
Pfizer Says It Will Seek FDA Approval For A Maternal RSV Vaccine This YearInitial trail results of the maternal vaccine showed promising results for Pfizer. The pharmaceutical company will seek FDA approval this week.
Read more »
RSV Vaccine Given During Pregnancy Protects Newborns: PfizerNew trial data from Pfizer shows promising results of a vaccine given to mothers during pregnancy that later protects infants in their first months from the worst effects RSV. MedTwitter
Read more »